| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Revenue | 179,987 | - |
| Total cost of revenue | 43,621 | - |
| Sales and marketing | 61,502 | - |
| Product development | 24,822 | - |
| General and administrative | 37,306 | - |
| Other segment items, net | -204,792 | - |
| Benefit from income taxes | -9,906 | - |
| Net loss | -182,150 | - |
| Depreciation and amortization | 2,312 | - |
| Amortization of intangible assets | 39,903 | - |
| Amortization of deferred contract costs | 11,931 | - |
| Equity-based compensation | 20,983 | - |
| Amortization of debt issuance costs | 380 | - |
| Write-off of deferred offering costs | 467 | - |
| (recovery of) provision for doubtful accounts receivable | -635 | - |
| Loss on partial extinguishment of debt | -507 | - |
| Non-cash restructuring charges | 352 | - |
| Goodwill impairment charges | 176,531 | - |
| Tra remeasurement | 10,623 | - |
| Changes in fair value of contingent consideration | -3,970 | - |
| Deferred income taxes | 10,310 | - |
| Accounts receivable | -19,351 | - |
| Prepaid expenses and other assets | 3,481 | - |
| Deferred contract costs | -9,376 | - |
| Contingent consideration | 0 | - |
| Accounts payable, accrued expenses and other liabilities | 353 | - |
| Deferred revenue | -1,468 | - |
| Net cash provided by operating activities | 51,057 | 35,370 |
| Purchases of property, equipment and other assets | 12,280 | 9,999 |
| Purchases of short-term investments | 64,065 | 64,065 |
| Maturities of short-term investments | -173,869 | -147,447 |
| Cash paid for acquisitions, net of cash acquired | 0 | 0 |
| Net cash provided by (used in) investing activities | 97,524 | 73,383 |
| Repayments of term loan | 250,625 | 248,438 |
| Proceeds from term loan | 175,000 | 175,000 |
| Payments of debt issuance costs | 1,660 | 1,660 |
| Taxes paid related to net share settlement of equity awards | 3,546 | 2,483 |
| Repurchases of class a common stock | 49,452 | 40,231 |
| Payments of contingent consideration | 0 | 0 |
| Payments under tra | 13,767 | 13,767 |
| Member distributions | 2,827 | 2,827 |
| Net cash used in financing activities | -146,877 | -134,406 |
| Net increase in cash and cash equivalents | 1,704 | -25,653 |
| Effect of exchange rate changes on cash | 1,235 | - |
| Cash and cash equivalents at beginning of period | 105,378 | - |
| Cash and cash equivalents at end of period | 108,317 | - |
Definitive Healthcare Corp. (DH)
Definitive Healthcare Corp. (DH)